Nalbufin injections, Nalbufin Serb, Nalbufin – Pharmex , Nalbuk .
It inhibits conditioned reflexes, has a sedative effect, causes dysphoria, miosis , excites the vomiting center. To a lesser extent than morphine, trimeperidine , fentanyl , it inhibits the respiratory center and affects the motility of the digestive tract.
Indications for use
Severe pain syndrome of various origins; as an additional means of pain relief in general anesthesia.
Method of administration and dosage
S / c, i / m, i / v. In case of pain syndrome – in / in or in / m at 0.15–0.3 mg / kg of body weight. You can re-enter, if necessary , every 4-6 hours. The maximum single dose is 0.3 mg / kg, the maximum daily dose is 2.4 mg / kg. The duration of the appointment is no more than 3 days.
If myocardial infarction is suspected – 10–20 mg IV slowly. If necessary, the dose can be increased to 30 mg. In the absence of a clear positive dynamics of pain syndrome – 20 mg again after 30 minutes.
For premedication – 100-200 mcg / kg.
For induction anesthesia – 0.3-1 mg / kg for 10-15 minutes, for maintaining anesthesia – 250-500 mcg / kg every 30 minutes. The initial single dose for children is 300 mcg / kg i / v, i / m, s / c. You can enter it again if necessary.
Lethargy, drowsiness, confusion, dizziness, headache, agitation, euphoria or depression, hallucinations; lability of blood pressure and heart rate; nausea, vomiting, dry mouth, dyspepsia, cramping pain; urticaria, anaphylactic or anaphylactoid shock, bronchospasm, laryngeal edema, itching, sneezing; pulmonary edema; decrease in the minute volume of respiration; increased sweating, soreness at the injection site, drug dependence, drug withdrawal syndrome.
Hypersensitivity to nalbuphine , marked respiratory depression and central nervous system, epileptic syndrome, intracranial hypertension, cranio – brain injury, acute alcohol intoxication, alcohol psychosis, acute surgical diseases of the abdominal cavity (before diagnosis), surgical interventions on the hepatobiliary system, opiate addiction. Use with caution in the elderly, with cachexia, hepatic or renal failure, respiratory failure, during pregnancy and lactation, in persons under the age of 18 years.
Manifested hypoventilation of the lungs, loss of consciousness, periodic breathing Cheyne – Stokes, pale skin, hypothermia, miosis , decreased blood pressure, cardio – vascular insufficiency, stupor, coma, depression of the respiratory center. Shows control and maintenance of adequate pulmonary ventilation, systemic hemodynamics and body temperature, oxygen therapy. With respiratory depression – IV Naloxone or Nalorphin .